Carmurit–T


Composition:
Each tablet contains:
Trimethoprim                 100 mg
Phenazopyridine HCl      25 mg

Properties:
Carmurit-T tablets contain Trimethoprim which acts as a synthetic antibacterial agent that blocks the production of tetrahydrofolic acid, thus interfers with bacterial biosynthesis of nucleic acids and proteins, and Phenazopyridine HCl which is excreted in the urine where it exerts a topical analgesic effect on the mucosa of the urinary tract.

Pharmacokinetics:
Following oral administration of Carmurit-T tablets, Trimethoprim is rapidly absorbed, it exists in the blood as unbound, protein bound and metabolized form.
Mean peak plasma concentrations occur 1–4 hours after administration of 100 mg dose. The half-life ranges from 8–10 hours. Excretion of Trimethoprim is primarily by the kidneys.
Phenazopyridine is rapidly excreted by the kidneys, with as much as 65% of an oral dose being excreted unchanged in the urine.

Indications & usage:
Carmurit-T tablets are indicated in:
- Symptomatic relief of pain, burning, urgency, frequency and other discomforts arising from irritation of the lower urinary tract mucosa.
- Treatment of initial episodes of uncomplicated urinary tract infection caused by Trimethoprim sensitive organisms.

Contraindications:
Carmurit-T tablets are contraindicated in individuals hypersensitive to any of the components of the drug, in those with documented megaloblastic anemia due to folate deficiency and in patients with renal insufficiency.

Side effects:
Some of the following side effects may occur in some cases:
Headache, rash, pruritus, gastrointestinal disturbances, methemoglobinemia, leukopenia and megaloblastic anemia, agranulocytosis & thrombocytopenia.

Drug interactions:
Concomitant administration of carmurit–T tablets and phenytoin can lead to excessive phenytoin effect.

Warnings & precautions:
- The presence of clinical signs such as sore throat and fever may be early indications of serious blood disorders.
Complete blood counts should be obtained if any of these signs are noted in a patient receiving Carmurit-T tablets.
The drug should be discontinued if a significant reduction in the count of any formed blood element is found.
- Carmurit-T tablets should be given with caution to patients with possible folate deficiency, impaired renal or hepatic function.

Information for patients:
•    Carmurit-T tablets produce an orange to red colour in the urine.
•    Staining of contact lenses is reported.

Pregnancy:
Carmurit-T tablets should be used during pregnancy if clearly needed.

Lactation:
Caution should be exercised when carmurit–T tablets are administered to a nursing woman.

Overdosage:
-    Acute overdosage: signs of acute overdosage include: nausea, vomiting, confusion, mental depression and methemoglobinemia which can be managed by methylene blue 1 to 2 mg/kg body weight.
-    Treatment also include gastric lavage and supportive measures.
-    Chronic overdosage: Symptoms of chronic overdosage include bone marrow depression, in this case the drug should be discontinued and the patient is given leucovorin 5-15 mg daily.

Dosage and administration:

One tablet every 12 hours after meals.
Treatment should not exceed 2 days.

Therapeutic category: Antibacterial &analgesic for urinary tract infection.

Legal category: Prescription only medicine (POM).


Package:
Box containing 20 tablets.

Storage:
Store in a dry place, at a temperature below 30° C, protect from light.

THIS IS A MEDICAMENT
Medicament is a product, which affects your health and its consumption contrary to instructions is dangerous for you. Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are the experts in medicines, their benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed.
- Do not repeat the same prescription without consulting your doctor.
- Keep all medicaments out of reach of children.

Council of Arab Health Ministers, Union of Arab Pharmacists.